Buserelin (Suprefact) is a hormonal therapy drug used to treat advanced prostate cancer. It is a medication which is used primarily in the treatment of prostate cancer and endometriosis. It is also used for other indications such as the treatment of premenopausal breast cancer, uterine fibroids, and early puberty, in assisted reproduction for female infertility, and as a part of transgender hormone therapy. In addition, buserelin is used in veterinary medicine. The medication is typically used as a nasal spray three times per day, but is also available for use as a solution or implant for injection into fat.
White or slightly yellowish powder, hygroscopic.
Gonad-stimulating principle.
ChEBI: Buserelin is an oligopeptide.
Suprefact
(Hoechst-Roussel).
Treatment of advanced prostate cancer and
endometriosis
Pituitary desensitisation in preparation for ovulation
induction regimens using gonadotrophins
Using too much Buserelin Injection may make you feel weak, nervous, dizzy and sick. You may also have a headache, hot flushes, stomach pain, swelling of the legs and breast pain. You may also have pain, bleeding or hardening of the skin at the site of injection
Metabolic inactivation by peptides occurs in the liver
and kidney. The drug is also inactivated by pituitary
membrane enzymes.
Excreted in the urine and bile as unchanged drug and
metabolites.
Buserelin contains 9 amino acids Glu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NHEt and having a molecular weight of 1239.44 Dalton.
Buserelin belongs to the group of gonadotrophin releasing hormone (gonadorelin) analogues (LHRH agonist). It acts on the pituitary gland which controls the amount of many different types of hormones (chemical messengers). It alters the amount of hormones, particularly the oestrogens androgens. This alteration of hormone levels can be exploited to treat cancers of the prostate gland, which are stimulated to grow by testosterone. Buserelin lowers the levels of testosterone, which starves the tumour of testosterone and causes it to shrink.
